Crescendo Bioscience to Feature New Data on Vectra® DA at 2014 ACR Meeting

Crescendo Bioscience to Feature New Data on Vectra® DA at 2014 ACR Meeting SALT LAKE CITY, Utah, Nov. 10, 2014 – Crescendo Bioscience, a wholly-owned subsidiary of Myriad Genetics, Inc. (NASDAQ: MYGN), today announced that new data on Vectra® DA will be featured at the 2014 American College of Rheumatology (ACR) Annual Meeting, Nov. 15–19, […]

Read More

Crescendo Bioscience Highlights New Clinical Data on Vectra® DA at ACR

Crescendo Bioscience Highlights New Clinical Data on Vectra® DA at ACR Data Show Vectra DA Is Better Predictor of Joint Damage in RA Patients SALT LAKE CITY, Utah, Nov. 19, 2014 – Crescendo Bioscience, a wholly-owned subsidiary of Myriad Genetics, Inc. (NASDAQ: MYGN), today presented new data that showed Vectra® DA is a better predictor […]

Read More

Crescendo Bioscience to Present Multiple Studies at 2014 EULAR Congress

Crescendo Bioscience to Present Multiple Studies at 2014 EULAR Congress Vectra® DA Identified Patients in SWEFOT Clinical Study at Higher Risk of Joint Damage SALT LAKE CITY, Utah, June 10, 2014 – Crescendo Bioscience, a wholly-owned subsidiary of Myriad Genetics, Inc. (NASDAQ: MYGN), today announced that Vectra® DA data will be featured in eight posters […]

Read More

Crescendo Bioscience’s Vectra® DA Predicts Radiographic Progression In Patients with Early Rheumatoid Arthritis

Crescendo Bioscience’s Vectra® DA Predicts Radiographic Progression In Patients with Early Rheumatoid Arthritis New Study Data Published in Annals of Rheumatic Diseases Add to Clinical Evidence SALT LAKE CITY, Utah, May 14, 2014 – Crescendo Bioscience, a wholly-owned subsidiary of Myriad Genetics, Inc. (Nasdaq: MYGN), today announced the online publication of a new study in […]

Read More